Disclaimer: The below article is sponsored, and the views in it do not represent those of ZyCrypto. Readers should conduct independent research before taking any actions related to the project mentioned in this piece. This article should not be regarded as investment advice.
In a landmark transaction, real operating company equity arrives on Solana-based tokenized capital formation for the first time.
First Block, Inc., a digital securities and tokenization infrastructure company, together with Onpharma Company (Delaware) and UK-based Crito Capital LLP, has announced the launch of what is believed to be the first Solana-based Security Token Offering (STO) for an established U.S. operating business — a structural turning point in the modernization of global private markets.
First Block has deployed its next-generation digital securities architecture to support a real-world operating company, while Onpharma brings genuine commercial substance to the offering: medical device technology for dentistry backed by recurring revenue, high gross margins, and a significant market opportunity.
The offering is available at sto.onpharma.com.
 
The Tokenization Framework
The STO deploys Solana blockchain infrastructure combining atomic settlement technology, programmable ownership architecture, and digital distribution capabilities — all structured within existing U.S. securities law. Where traditional private markets have long struggled with fragmented, multi-intermediary processes, this tokenized framework enables issuance, settlement, and cross-border distribution to qualified investors quickly, transparently, and at low cost. Secondary transactions occur on-chain across compatible wallets, subject to KYC controls, delivering near-instantaneous settlement, secondary trading liquidity, and international accessibility under Regulation S and other applicable frameworks.
The STO Structure
A Security Token Offering represents and transfers ownership rights in a company’s common stock through blockchain-based digital tokens, rather than traditional share registers. The Onpharma STO is structured as a Regulation S offshore issuance to non-U.S. investors — combining the legal certainty of an exempt securities offering with the operational efficiency of Solana infrastructure, settling and distributing at speeds and costs traditional private markets simply cannot match.
Onpharma: The Case
Onpharma occupies a distinctive position in global dental technology. Its Onset EZ local anesthetic buffering product is already used to buffer millions of dental injections annually, addressing a problem that has gone largely unsolved for decades: the slow, uncomfortable, and unreliable performance of dental local anesthetics. The Onset EZ Pen requires no assembly or specialized training and integrates directly into existing clinical workflows to improve the patient experience.
The company sits at a post-validation, pre-scale inflection point — infrastructure, supply chain, regulatory compliance, and initial commercialization are complete, while the growth phase is just beginning. Septodont’s February 2025 market entry validated anesthetic buffering as an emerging standard of care, reducing category risk and increasing market awareness. The disposable Onset EZ Pen provides operational leverage through scalable direct marketing, customer conversion, and repeat consumable revenue. The global dental anesthesia buffering market is valued at $2 billion, projected to reach $2.65 billion by 2030. Capital raised through the offering will extend field sales and expand direct selling via the company’s recently deployed AI marketing tools.
The Infrastructure
First Block’s digital securities architecture underpins the transaction end-to-end — from issuance and compliance through to Solana-based settlement and distribution. It compresses conventional private placement infrastructure, fragmented custodial arrangements, manual processing, and multi-intermediary chains into a single programmable, blockchain-enabled system built for the scale, speed, and wallet-level accessibility that international investors increasingly demand.
Crito Capital LLP, an FCA-authorised investment banking and advisory platform focused on institutional capital formation, is providing structuring and advisory services for the offering.
“This is larger than a traditional financing,” said Daniel P. Cannon, CEO of First Block. “We believe this transaction represents the beginning of the convergence between capital markets and Solana-based securities infrastructure. The STO itself is the story, but it starts with a real operating company, a real product, and exceptional revenue growth potential.”
“Onpharma has spent years building a real operating business around a simple clinical objective: making local anaesthetic better for dentists and patients,” said Matt Stepovich, Onpharma’s CEO. “This offering allows us to present a validated, revenue-generating medical device platform to a wider base of qualified international investors via a structure that reflects how capital markets are evolving. Combining Onpharma’s real-world commercial traction with First Block’s Solana-based securities infrastructure is an important step in making growth capital formation more efficient, accessible and transparent.”
Additional details on the offering structure and participation frameworks are available on the STO landing page at sto.onpharma.com.